



April 28, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Proceedings of the NCLT convened meeting of the Equity Shareholders of J.B. Chemicals & Pharmaceuticals Limited (“Company”)

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

In terms of Regulation 30 of the Listing Regulations, please find below gist of proceedings of the Hon’ble National Company Law Tribunal, Ahmedabad Bench (“NCLT”) convened meeting of the Equity Shareholders of the Company held on Tuesday, April 28, 2026 at 02:00 p.m. (IST) through video conferencing (“VC”) / other audio-visual means (“OAVM”) (“Meeting”).

GIST OF PROCEEDINGS:

The NCLT convened Meeting of Equity Shareholders of the Company commenced at 02:00 p.m. (IST) and concluded at 02:33 p.m. (IST).

With the requisite quorum being present, Mr. Mahesh Gupta, Chairman appointed for NCLT convened Meeting called the Meeting to order.

Registered Office:
J. B. Chemicals & Pharmaceuticals Limited
CIN: L24390GJ1976PLC173077
302, Iscon Mall, Star India Bazar Building,
Opp. Jodhpur BRTS Satellite,
Ahmedabad- 380015, Gujarat, India
Email: secretarial@jbpharma.com

Corporate Office:
J. B. Chemicals & Pharmaceuticals Limited
CIN: L24390GJ1976PLC173077
Energy IT Park, Unit A, 3rd Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai 400 025.
Tel.:+91 22 2439 5200/5500



www.jbpharma.com



GOOD PEOPLE
for **GOOD HEALTH**

The proposed Scheme of Amalgamation of the Company with Torrent Pharmaceuticals Limited and their respective shareholders (“Scheme”) as set out in the Notice of NCLT convened Meeting of Equity Shareholders has been duly approved by the Equity Shareholders of the Company with requisite majority under the provisions of Section 230(6) of the Companies Act, 2013 (“Act”) i.e. majority of the Equity Shareholders and three fourths in value of the Equity Shareholders who have casted their votes through remote e-voting and e-voting at the meeting.

The above business was transacted by remote e-voting and e-voting at the NCLT convened Meeting as required under the Act, Listing Regulations and the circulars issued by the Ministry of Corporate Affairs.

The results of remote e-voting and e-voting at the meeting along with Scrutinizer’s Report and results of voting as required under Regulation 44(3) of Listing Regulations will be disclosed to the Stock Exchanges separately.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis

Vice President – Secretarial

& Company Secretary

Registered Office:

J. B. Chemicals & Pharmaceuticals Limited

CIN: L24390GJ1976PLC173077

302, Iscon Mall, Star India Bazar Building,

Opp. Jodhpur BRTS Satellite,

Ahmedabad- 380015, Gujarat, India

Email: secretarial@jbpharma.com

Corporate Office:

J. B. Chemicals & Pharmaceuticals Limited

CIN: L24390GJ1976PLC173077

Energy IT Park, Unit A, 3rd Floor, Appa Saheb Marathe Marg,

Prabhadevi, Mumbai 400 025.

Tel.:+91 22 2439 5200/5500



www.jbpharma.com